Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide platform. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market.
Novan presents preclinical data from SB414 program
Posters presentations provide mechanistic evidence for SB414 as a potential treatment for psoriasis and atopic dermatitis
Novan reports topline results with SB208 in Phase 2 Trial
SB208: A potential broad-spectrum antifungal gel for the treatment of infections of the skin and nails
Novan reshapes executive management team
Paula Brown Stafford appointed Chief Development Officer. Stanley Hollenbach promoted to Senior VP of R&D
Phase 2 results with SB206 to be presented at 2017 AAD annual meeting
SB206: A first-in-class, topical anti-viral gel in clinical development for the treatment of viral skin infections
Novan licenses SB204 to Sato for acne in Japan
